Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Tracheotomy With and Without Dual Antiplatelet Therapy (PDT and (D)APT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05058469
Recruitment Status : Not yet recruiting
First Posted : September 27, 2021
Last Update Posted : October 11, 2021
Sponsor:
Information provided by (Responsible Party):
Asklepios Neurological Clinic Bad Salzhausen

Brief Summary:

Platelet-inhibiting drugs are often used after vascular interventions. Patients who require such therapies are often critically ill, are treated in intensive care units and often require long-term ventilation. For long-term ventilation a tracheotomy is necessary, which is usually performed as a percutaneous dilatative tracheotomy (PDT). As part of this intervention, there is (theoretically) an increased risk of bleeding/an increased rate of complications in patients with a antiplatelet therapy. In addition, there are various techniques for performing a PDT.

The current study aims to investigate the frequency of bleeding/complications taking into account the technique used in PDT.


Condition or disease Intervention/treatment
Tracheostomy Hemorrhage Device: Tracheotomy

Layout table for study information
Study Type : Observational
Estimated Enrollment : 300 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Evaluation of the Safety of Percutaneous Tracheotomies in Intensive Care Patients With and Without Antiplatelet Therapy and Comparison of Two Tracheotomy Techniques
Estimated Study Start Date : December 2021
Estimated Primary Completion Date : June 2022
Estimated Study Completion Date : December 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bleeding

Group/Cohort Intervention/treatment
Tracheotomy without antiplatelet therapy+technique 1 Device: Tracheotomy
Tracheotomy in patients +/- antiplatelet therapy

Tracheotomy under antiplatelet therapy+technique 1 Device: Tracheotomy
Tracheotomy in patients +/- antiplatelet therapy

Tracheotomy without antiplatelet therapy+technique 2 Device: Tracheotomy
Tracheotomy in patients +/- antiplatelet therapy

Tracheotomy under antiplatelet therapy+technique 2 Device: Tracheotomy
Tracheotomy in patients +/- antiplatelet therapy




Primary Outcome Measures :
  1. Measurement of bleeding during Percutaneous Dilational Tracheostomy (PDT) with and without antiplatelet therapy (AP). [ Time Frame: 3 days ]
    • bleeding (yes/no)
    • intervention (yes/no)
    • decrease (>= 1 g/dl) of hemoglobin (yes/no)
    • number of blood transfusion(s)


Secondary Outcome Measures :
  1. - Does the technique of PDT affect the bleeding rate? - How often are recognizable cartilage pin fractures in the context of a PDT? - Influence of AP and PDT technology on the frequency of need for a blood transfusion? [ Time Frame: 14 days ]
    cartilage pin fractures seen in endoscopy



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Sampling Method:   Non-Probability Sample
Study Population
Patients who underwent Percutaneous Dilational Tracheostomy within the last 5 years.
Criteria

Inclusion Criteria:

  • Patients who underwent Percutaneous Dilational Tracheostomy

Exclusion Criteria:

  • none

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05058469


Contacts
Layout table for location contacts
Contact: Dirk Bandorski, MD +496043804212 d.bandorski@asklepios.com

Locations
Layout table for location information
Germany
Neurologische Klinik Bad Salzhausen
Nidda, Germany, 63667
Sponsors and Collaborators
Asklepios Neurological Clinic Bad Salzhausen
Layout table for additonal information
Responsible Party: Asklepios Neurological Clinic Bad Salzhausen
ClinicalTrials.gov Identifier: NCT05058469    
Other Study ID Numbers: PDT and (D)APT
First Posted: September 27, 2021    Key Record Dates
Last Update Posted: October 11, 2021
Last Verified: September 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hemorrhage
Pathologic Processes